Twist Bioscience Q1 FY2025 revenue $88.7M (+24% YoY), gross margin 48.3%, net loss narrows to $31.6M

Twist Bioscience Corp

2025-Q1 EPS reported -$0.53 revenue$88,713,000

Total revenue $88.7M vs $71.5M YoY; SynBio +28% to $34.4M, NGS +23% to $48.6M.
Gross margin improved 7.8 points to 48.3% from 40.5% in prior year period.
Net loss per share ($0.53) vs ($0.75) YoY; adjusted EBITDA ($16.3M) vs ($27.8M).
FY2025 revenue guidance $372M-$379M; expects gross margin over 50% in Q4 FY2025.
Cash and short-term investments $270.8M at Dec 31, 2024; shipped to ~2,376 customers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.